Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure

Circulation

Volumn 141, Issue 5, 2020, Pages 352-361

  Solomon, Scott D ^a   Vaduganathan, Muthiah ^a   Claggett, Brian L ^a   Packer, Milton ^b,c   Zile, Michael ^d,e   Swedberg, Karl ^f,g   Rouleau, Jean ^h   Pfeffer, Marc A ^a   Desai, Akshay ^a   Lund, Lars H ⁱ   Kober, Lars ^j   Anand, Inder ^k   Sweitzer, Nancy ^l   Linssen, Gerard ^m   Merkely, Bela ⁿ   Luis Arango, Juan ^o   Vinereanu, Dragos ^p   Chen, Chen Huan ^q   Senni, Michele ^r   Sibulo, Antonio ^s   Boytsov, Sergey ^t   Shi, Victor ^u   Rizkala, Adel ^u   Lefkowitz, Martin ^u   Mcmurray, John J V ^v   more..

^a HARVARD MEDICAL SCHOOL   (United States)

^b BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^e RALPH H JOHNSON VA MEDICAL CENTER   (United States)

^f UNIVERSITY OF GOTHENBURG   (Sweden)

^g NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^h MONTREAL HEART INSTITUTE   (Canada)

ⁱ KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^j Rigshospitalet   (Denmark)

^k UNIVERSITY OF MINNESOTA   (United States)

^l UNIVERSITY OF ARIZONA   (United States)

^m Twente Hospital Group   (Netherlands)

ⁿ SEMMELWEIS UNIVERSITY   (Hungary)

^o Guatemalan Heart Institute   (Guatemala)

^p CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^q NATIONAL YANG MING UNIVERSITY   (Taiwan)

^r PAPA GIOVANNI XXIII HOSPITAL   (Italy)

^s ST LUKE S MEDICAL CENTER   (Philippines)

^t N N BLOKHIN NATIONAL MEDICAL RESEARCH CENTER OF ONCOLOGY   (Russian Federation)

^u NOVARTIS PHARMA AG   (Switzerland)

^v UNIVERSITY OF GLASGOW   (United Kingdom)

more..

Author keywords

clinical efficacy; heart failure; sacubitril valsartan; ventricular ejection fraction

Indexed keywords

AMINOBUTYRIC ACID DERIVATIVE; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; SACUBITRIL-VALSARTAN; TETRAZOLE DERIVATIVE;

AGED; DRUG EFFECT; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; HUMAN; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; TREATMENT OUTCOME;

AGED; AMINOBUTYRATES; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; STROKE VOLUME; TETRAZOLES; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT;

EID: 85076157482     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.119.044586     Document Type: Article

References (19)

1. Rossignol P, Hernandez AF, Solomon SD, Zannad F. Heart failure drug treatment. Lancet. 2019;393:1034-1044. doi: 10.1016/S0140-6736(18)31808-7
2. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, et al; ESC Scientific Document Group. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129-2200. doi: 10.1093/eurheartj/ehw128
3. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, Drazner MH, Filippatos GS, Fonarow GC, Givertz MM, et al. 2017 ACC/ AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/ American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol. 2017;70:776-803. doi: 10.1016/j.jacc.2017.04.025
4. Lund LH, Claggett B, Liu J, Lam CS, Jhund PS, Rosano GM, Swedberg K, Yusuf S, Granger CB, Pfeffer MA, et al. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. Eur J Heart Fail. 2018;20:1230-1239. doi: 10.1002/ejhf.1149
5. Solomon SD, Claggett B, Lewis EF, Desai A, Anand I, Sweitzer NK, O'Meara E, Shah SJ, McKinlay S, Fleg JL, et al; TOPCAT Investigators. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. Eur Heart J. 2016;37:455-462. doi: 10.1093/eurheartj/ehv464
6. Kraigher-Krainer E, Shah AM, Gupta DK, Santos A, Claggett B, Pieske B, Zile MR, Voors AA, Lefkowitz MP, Packer M, et al; PARAMOUNT Investigators. Impaired systolic function by strain imaging in heart failure with preserved ejection fraction. J Am Coll Cardiol. 2014;63:447-456. doi: 10.1016/j.jacc.2013.09.052
7. Shah AM, Claggett B, Sweitzer NK, Shah SJ, Anand IS, Liu L, Pitt B, Pfeffer MA, Solomon SD. Prognostic importance of impaired systolic function in heart failure with preserved ejection fraction and the impact of spironolactone. Circulation. 2015;132:402-414. doi: 10.1161/CIRCULATIONAHA.115.015884
8. Lam CS, Solomon SD. The middle child in heart failure: heart failure with mid-range ejection fraction (40-50%). Eur J Heart Fail. 2014;16:1049-1055. doi: 10.1002/ejhf.159
9. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, et al; PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993-1004. doi: 10.1056/NEJMoa1409077
10. Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, et al; PARAGON-HF Investigators and Committees. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019;381:1609-1620. doi: 10.1056/NEJMoa1908655
11. Novartis Position on Clinical Study Transparency-Clinical Study Registration, Results Reporting and Data Sharing 2016. https://www.novartis. com/sites/www.novartis.com/files/clinical-trial-data-transparency.pdf. Accessed January 20, 2020.
12. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau J, Shi VC, Solomon SD, Swedberg K, et al; PARADIGM-HF Committees and Investigators. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF). Eur J Heart Fail. 2013;15:1062-1073. doi: 10.1093/eurjhf/hft052
13. Solomon SD, Rizkala AR, Gong J, Wang W, Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez F, Packer M, et al. Angiotensin receptor neprilysin inhibition in heart failure with preserved ejection fraction: rationale and design of the PARAGON-HF trial. JACC Heart Fail. 2017;5:471-482. doi: 10.1016/j.jchf.2017.04.013
14. Harrell FE. Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis. New York: Springer; 2001.
15. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, Drazner MH, Filippatos GS, Fonarow GC, Givertz MM, et al. 2017 ACC/ AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/ American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017;136:e137-e161. doi: 10.1161/CIR.0000000000000509
16. Shah AM, Cikes M, Prasad N, Li G, Getchevsky S, Claggett B, Rizkala A, Lukashevich I, O'Meara E, Ryan JJ, et al. for the PARAGON-HF Investigators. Cardiac structure and function in heart failure with preserved ejection fraction: the echocardiographic study of the prospective comparison of ARNI with ARB global outcomes in HF with preserved ejection fraction (PARAGON-HF) trial. J Am Coll Cardiol. In Press. 10.1016/j.jacc.2019.09.063
17. Mohammed SF, Mirzoyev SA, Edwards WD, Dogan A, Grogan DR, Dunlay SM, Roger VL, Gertz MA, Dispenzieri A, Zeldenrust SR, et al. Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction. JACC Heart Fail. 2014;2:113-122. doi: 10.1016/j.jchf. 2013.11.004
18. Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, Kristen AV, Grogan M, Witteles R, Damy T, et al; ATTR-ACT Study Investigators. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379:1007-1016. doi: 10.1056/NEJMoa1805689
19. Lin FY, Devereux RB, Roman MJ, Meng J, Jow VM, Jacobs A, Weinsaft JW, Shaw LJ, Berman DS, Callister TQ, et al. Cardiac chamber volumes, function, and mass as determined by 64-multidetector row computed tomography: mean values among healthy adults free of hypertension and obesity. JACC Cardiovasc Imaging. 2008;1:782-786. doi: 10.1016/j.jcmg.2008.04.015